Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System

Varování

Publikace nespadá pod Lékařskou fakultu, ale pod Středoevropský technologický institut. Oficiální stránka publikace je na webu muni.cz.

Autoři	VAN EIMEREN T. ANTONINI A. BERG D. BOHNEN N. CERAVOLO R. DRZEZGA A. HÖGLINGER G. HIGUCHI M. LEHERICY S. LEWIS S. MONCHI O. NESTOR P. ONDRUS M. PAVESE N. PERALTA M.C. PICCINI P. PINEDA-PARDO J.A. REKTOROVÁ Irena RODRÍGUEZ-OROZ M.
Rok publikování	2019
Druh	Článek v odborném periodiku
Časopis / Zdroj	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Fakulta / Pracoviště MU	Středoevropský technologický institut
Citace
www	https://alz-journals.onlinelibrary.wiley.com/doi/full/10.1016/j.dadm.2019.01.011
Doi	http://dx.doi.org/10.1016/j.dadm.2019.01.011
Klíčová slova	Biomarker; CDB; CBS; MRI;MSA
Popis	Therapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.